Sign In
Buy BHVN
$10.81
+0.680 (+6.71%)
At Close: Jun 03, 2026
Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2025 Financial Results
04:05pm, Monday, 02'nd Mar 2026
Prioritizing three key, late-stage clinical programs including Molecular Degrader of Extracellular Proteins (MoDETM) and Targeted Removal of Aberrant Protein (TRAPTM) extracellular protein degradatio
Is Biohaven Ltd. (BHVN) Stock Outpacing Its Medical Peers This Year?
10:40am, Tuesday, 10'th Feb 2026
Here is how Biohaven Ltd. (BHVN) and Caribou Biosciences, Inc. (CRBU) have performed compared to their sector so far this year.
Does Biohaven Ltd. (BHVN) Have the Potential to Rally 82.16% as Wall Street Analysts Expect?
10:56am, Monday, 09'th Feb 2026
The consensus price target hints at an 82.2% upside potential for Biohaven Ltd. (BHVN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings es
Goldman Sachs Just Upgraded These 3 Stocks to a Buy Rating
09:26am, Monday, 09'th Feb 2026
Goldman initiated a buy rating on Biohaven targeting its IgAN treatment in an over $40B U.S. market.
Pre-Market Stock Futures: Futures are trading higher as we prepare to wrap up one of the worst trading weeks in some time. The song remains the same as the rotation out of the tech trade continues to
Biohaven (BHVN) Stock Is Trending Overnight — Here's What You Should Know
09:48pm, Wednesday, 14'th Jan 2026
Biohaven Ltd. shares surged 3.42% in after-hours trading following an SEC filing that detailed investor presentations and updates on its drug pipeline.
Reports positive early clinical experience from first and only clinically validated, extracellular protein degraders using Biohaven's proprietary MoDE™ and next-generation, highly selective TRAP™
Biohaven to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026
07:00am, Wednesday, 07'th Jan 2026
NEW HAVEN, Conn., Jan. 7, 2026 /PRNewswire/ -- Biohaven Ltd.
Biohaven Stock Gaps Lower on Failed Phase 2 Drug Trial
10:25am, Friday, 26'th Dec 2025
Biohaven Ltd (NYSE:BHVN) stock is down 3.2% to trade at $10.46 at last glance, amid reports that the biopharmaceutical name's drug to treat major depressive disorder did not meet the primary goal o
Cautiously Bullish After Biohaven's Cash Runway And Dilution Risk Rise
09:24am, Friday, 26'th Dec 2025
BHVN's investment case definitely weakened after Opakalim's Phase 2 MDD miss. This also means they'll discontinue their psychiatric development. BHVN's pipeline remains diverse, but key assets like Op
Stock Futures Muted as Traders Return from Christmas Break
09:21am, Friday, 26'th Dec 2025
Stock futures are quiet as investors return from Christmas, with all three major indexes eyeing weekly gains
Biohaven Misses The Mark In Depression Trial, Stock Falls
08:20am, Friday, 26'th Dec 2025
On Wednesday, Biohaven Ltd. (NYSE: BHVN) reported results from a Phase 2 proof-of-concept study evaluating BHV-7000 for major depressive disorder (MDD).
Stock Market Today: Dow Jones, S&P 500 Futures Slip After Christmas Day—Nvidia, Sobr Safe, Biohaven In Focus
05:09am, Friday, 26'th Dec 2025
U.S. stock futures slipped on Friday after Wednesday's higher close. Futures of major benchmark indices fell.
Nvidia, Sobr Safe And 3 Stocks To Watch Heading Into Friday
03:19am, Friday, 26'th Dec 2025
US stock futures slightly lower. Stocks to watch: NVIDIA, Dynavax, Sobr Safe, Davis Commodities, Biohaven.
ARS Investment Partners LLC Sells 85,577 Shares of Biohaven Ltd. $BHVN
03:19am, Thursday, 25'th Dec 2025
ARS Investment Partners LLC decreased its stake in shares of Biohaven Ltd. (NYSE: BHVN) by 7.2% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund
